Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors

被引：32

作者：

Zhao, Feng ^{[1
]}

Lin, Zhaohu ^{[1
]}

Wang, Feng ^{[1
]}

Zhao, Weili ^{[1
]}

Dong, Xiaochun ^{[1
]}

机构：

[1] Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 19期

关键词：

EGFR inhibitors; Anti-tumor agents; Anilinoquinazolines; Four-membered heterocycles; CANCER; GEFITINIB; MECHANISM; OXETANES; ANALOGS;

D O I：

10.1016/j.bmcl.2013.07.049

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report herein the design and synthesis of novel azaspirocycle or azetidine substituted 4-anilinoquinazoline derivatives. The EGFR inhibitory activities and in vitro antitumor potency of these newly synthesized compounds against two lung cancer cell lines HCC827 and A549 were evaluated. Most of the target compounds possess good inhibitory potency. In particular, compounds 21g with 2-oxa-6-azaspiro[3.4] octane substituent was found to possess higher EGFR inhibitory activities and similar antitumor potency comparing to the lead compound gefitinib with improved water solubility. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：5385 / 5388

页数：4

共 23 条

[1] Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].

Bridges, AJ ;

Zhou, H ;

Cody, DR ;

Rewcastle, GW ;

McMichael, A ;

Showalter, HDH ;

Fry, DW ;

Kraker, AJ ;

Denny, WA .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276

[2]

Burkhard J. A., 2010, ORG LETT, V12, P1944

[3] Synthesis of Azaspirocycles and their Evaluation in Drug Discovery [J].

Burkhard, Johannes A. ;

Wagner, Bjoern ;

Fischer, Holger ;

Schuler, Franz ;

Mueller, Klaus ;

Carreira, Erick M. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2010, 49 (20) :3524-3527

[4]

Chilin A., 2010, J MED CHEM, V1862, P53

[5]

Ciardiello F, 2001, CLIN CANCER RES, V7, P2958

[6] Mechanism of action of erbB tyrosine kinase inhibitors [J].

Fry, DW .

EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :131-139

[7] Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors [J].

Hu, Shaojing ;

Xie, Guojian ;

Zhang, Don X. ;

Davis, Charles ;

Long, Wei ;

Hu, Yunyan ;

Wang, Fei ;

Kang, Xinshan ;

Tan, Fenlai ;

Ding, Lieming ;

Wang, Yinxiang .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (19) :6301-6305

[8] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[9] Protein kinase inhibitors as a therapeutic modality [J].

Levitzki, A .

ACCOUNTS OF CHEMICAL RESEARCH, 2003, 36 (06) :462-469

[10] RETRACTED: Synthesis of gefitinib from methyl 3-hydroxy-4-methoxy-benzoate (Retracted article. See vol. 12, pg. 2160, 2007) [J].

Li, Ming Dong ;

Zheng, You Guang ;

Ji, Min .

MOLECULES, 2007, 12 (03) :673-678

← 1 2 3 →